Skip to Main Content

The revolving door between the U.S. Food and Drug Administration and the pharmaceutical industry turned again this week when Lupin, one of India’s biggest drug companies, hired an agency official who oversaw manufacturing facilities, including a plant that has been cited for ongoing problems.

The company hired Diana Amador-Toro as senior vice president for global compliance after she spent more than 38 years working at the FDA, where she was most recently district director at the New Jersey office and also a division I director in the Office of Pharmaceutical Quality Operations.


The job change comes less than a month after FDA inspectors found more than a dozen issues at a Lupin facility in Somerset, N.J., according to a notice the company filed with the Bombay Stock Exchange. And last June, Amador-Toro was one of two FDA officials who signed a warning letter sent to Lupin about manufacturing problems found at the location during an inspection in November 2020.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.